Curosurf/Budesonide for Infants With Respiratory Distress Syndrome
Status:
Completed
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome
usually need the second or more pulmonary surfactant and is easier to developing to
Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome,
Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is
Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of
Brochopulmonary dysplasia.
Phase:
N/A
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University